Trial intelligence / Profile preview

BGM0504 Injection in Overweight or Obese Non-diabetic Adults

CTR20233198Phase 2Completed

Sponsor
Borray New Creation Biopharmaceutical Technology
Start
Oct 2023
Modality
Peptides
Countries
1
01

Overview

A Phase 2 trial of BGM0504 in obesity, Overweight, sponsored by Borray New Creation Biopharmaceutical Technology. Started Oct 2023; status: completed.

02

Drugs

BGM0504
03

Conditions

obesityOverweight

Beyond the preview

Go deeper on CTR20233198.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20233198.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call